Dr. Christine Durand

Dr. Robin Avery is an infectious disease physician who joined the Johns Hopkins faculty in 2012, with two decades of experience in transplant infectious disease. She is a past chair of the American Society of Transplantation (AST) Infectious Disease Community of Practice, was a co-editor of the first edition of the AST ID Guidelines, and serves on a Guidelines Committee for the Infectious Disease Society of America (IDSA) on immunizations in the immunocompromised host. She was the founding head of the Transplant Infectious Disease Section at the Cleveland Clinic and served as the founding director of the Cleveland Clinic Transplant ID Special Fellowship, authoring a curriculum that served as the basis for curricula later endorsed by the AST and IDSA. Her clinical and research interests include pre-transplant donor and recipient evaluation, and prevention and treatment of post-transplant infections, particularly transplant-associated viruses, viral load monitoring, novel therapies for CMV, hypogammaglobulinemia, immunizations, and strategies for safer living post-transplant. She has a strong interest in patient education and co-authored the script for a video designed to educate patients on decreasing post-transplant infection risks. Dr. Avery is highly rated in 9 conditions, according to our data. Her top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Sepsis.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. Dr. Sulkowski is highly rated in 4 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.

Dr. Anna Durbin is an associate professor at the Johns Hopkins University School of Medicine. Her area of clinical expertise is infectious disease. Dr. Durbin earned her M.D. from Wayne State University School of Medicine. She completed her residency and performed a fellowship in infectious diseases at Detroit Medical Center. She has expertise in the evaluation of live attenuated flavivirus vaccines, primary dengue and West Nile virus vaccines, and the early evaluation of malaria vaccines. She has served on national and international advisory boards and committees related to dengue and malaria vaccine safety. An important research interest of hers is studying the immunopathogenesis of dengue infection and disease. In addition to her clinical studies, her laboratory is also developing an animal model of dengue using rhesus macaques. Dr. Durbin is highly rated in 11 conditions, according to our data. Her top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Arbovirosis, and Yellow Fever.